Berkshire Biomedical

07/07/2025

Berkshire Biomedical Announces that Its De Novo Application for Marketing Authorization of Its Computerized Oral Prescription Administration (COPA™) System Has Been Accepted for Review by the FDA.

This is a major accomplishment for the Company and ultimately for future patients and I want to thank the Berkshire team and all expert advisors, contractors, and vendor partners who have worked tirelessly over many years to make this milestone possible.

Read the full press release here.
https://www.berkshirebiomedical.com/news.php?p=51

The COPA System is currently under review by the U.S. Food and Drug Administration and is not available for commercial sale.

06/02/2025

Berkshire Biomedical Awarded NIH Research Grant to Support Clinical Study Program to Evaluate Patient Retention and Other Benefits of the COPA™ System for Take-Home Methadone Medication Management.

We are pleased to share exciting news that Berkshire was just awarded the first phase of a two-phase Fast-Track Small Business Innovation Research (SBIR) grant (1 R44DA061908-01A1) from the National Institutes of Health’s (NIH) National Institute of Drug Abuse (NIDA).

Valued at approximately $2.9 million over 30 months, the two-phase grant will support ex*****on of a clinical study to evaluate patient retention and other benefits of the Company’s COPA™ System for Take-Home Methadone Medication Management as part of Medication for Opioid User Disorder (MOUD) treatment. Phase I funds of approximately $326,400 will support the ex*****on of a single-site study. Receipt of the approximate $2.55 million Phase II award will support the ex*****on of an open-label, randomized, parallel multi-site study, which will be contingent on an assessment of the Phase I report, as well as the review and approval of any other documentation necessary for continuation and availability of NIH funds.

Read the full press release here.

https://www.berkshirebiomedical.com/news.php?p=50

The COPA System is currently under development, has NOT been reviewed by the U.S. Food and Drug Administration and is not available for commercial sale.

04/29/2025

Our Offering is Wrapping Up. One day left to get a piece of Berkshire Biomedical.
View our campaign at Start Engine https://bit.ly/3ESrnt4

This Reg CF offering is made available through StartEngine Primary LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.

04/15/2025

Thank you to everyone who attended our recent technology-focused webinar showcasing COPA™. The session, led by CEO John Timberlake and Head of Operations Christy Corey, provided attendees with a demonstration of our medication dispensing system which is designed to deliver doses only to an Authenticated Intended User (AIU™). For those that missed it you can view it here.

COPA™ is under development and has not been authorized for commercial sale by the FDA. Future expectations and potential market opportunities involve risks and uncertainties, including the risk that the product may not receive FDA approval or achieve the projected market potential. Actual results may differ materially from those expressed or implied. Investors should be aware of the inherent risks associated with investing in early-stage development companies.

This is "How COPA™ Delivers the Right Medication to the Right Person, in the Right Amount, at the Right Time" by Berkshire on Vimeo, the home for…

04/04/2025

We had a strong turnout for the first session of our 4-part live webinar series, with great engagement and insightful Q&A! Thank you to everyone who joined us. If you missed it, don’t worry, you can still catch the recording. https://vimeo.com/1072423469/b906fa8ca3

Check out our crowd-funding campaign at StartEngine by searching Berkshire Biomedical on the site.

COPA™ is under development and has not been authorized for commercial sale by the FDA. Future expectations and potential market opportunities involve risks and uncertainties, including the risk that the product may not receive FDA approval or achieve the projected market potential. Actual results may differ materially from those expressed or implied. Investors should be aware of the inherent risks associated with investing in early-stage development companies.

This is "Revolutionizing Patient-Empowered Medication Delivery with Remote Monitoring – Why Now_" by Berkshire on Vimeo, the home for high quality…

03/21/2025

According to Dr. Kathleen Brady, an experienced clinical and translational researcher with over 30 years in addiction and psychiatric disorders, there are critical gaps in at home methadone treatment.

COPA is designed to address these gaps by implementing a secure dispensing system that verifies patient identity, ensures precise daily dosing, and provides real-time monitoring. Learn more about our equity crowdfunding at https://www.startengine.com/offering/berkshirebiomedical

COPA™ is under development and has not been authorized for commercial sale by the FDA.
This Reg CF offering is made available through StartEngine Primary LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

03/03/2025

Every 6 minutes, someone dies from an opioid overdose. COPA™ is here to change that. With dual biometrics and real-time monitoring, we’re transforming medication delivery and saving lives. invest now. Learn more about our equity crowdfunding at https://www.startengine.com/offering/berkshirebiomedical

This Reg CF offering is made available through StartEngine Primary LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

03/01/2025

Investing in Berkshire Biomedical means joining the fight against the opioid crisis as we work to enable those already affected to receive at-home treatment with COPA™, a groundbreaking, patented device designed for secure, patient self-administered medication management.

Learn how to invest at StartEngine’s Berkshire Offering Page. https://bit.ly/3ESrnt4

The COPA System is currently under development, has NOT been reviewed by the U.S. Food and Drug Administration and is not available for commercial sale.

This Reg CF offering is made available through StartEngine Primary LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

02/26/2025

𝗕𝗲𝗿𝗸𝘀𝗵𝗶𝗿𝗲 𝗕𝗶𝗼𝗺𝗲𝗱𝗶𝗰𝗮𝗹'𝘀 𝗖𝘂𝗿𝗿𝗲𝗻𝘁 𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀 𝗦𝗵𝗼𝘄 𝗦𝘁𝗿𝗼𝗻𝗴 𝗦𝘂𝗽𝗽𝗼𝗿𝘁 𝘄𝗶𝘁𝗵 $𝟮𝟬𝟬,𝟬𝟬𝟬+ 𝗶𝗻 𝗔𝗱𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹 𝗙𝘂𝗻𝗱𝗶𝗻𝗴

Consider joining us in advancing a treatment solution with the potential to make a significant impact on patient care. Learn more about how to invest at https://www.startengine.com/offering/berkshirebiomedical

Important Notice: COPA™ is under development and has not been authorized for commercial sale by the FDA. Future expectations and potential market opportunities involve risks and uncertainties, including the risk that the product may not receive FDA approval or achieve the projected market potential. Actual results may differ materially from those expressed or implied. Investors should be aware of the inherent risks associated with investing in early-stage development companies.

This Reg CF offering is made available through StartEngine Primary LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

02/24/2025

𝗧𝗼𝗱𝗮𝘆 𝗕𝗲𝗿𝗸𝘀𝗵𝗶𝗿𝗲 𝗕𝗶𝗼𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗟𝗮𝘂𝗻𝗰𝗵𝗲𝗱 𝗜𝘁𝘀 𝗙𝗶𝗿𝘀𝘁 𝗣𝘂𝗯𝗹𝗶𝗰 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗖𝗮𝗺𝗽𝗮𝗶𝗴𝗻!
We're revolutionizing personalized medication delivery with our innovative COPA™ technology, designed to enhance treatment accessibility and patient wellness. Did you know? Only 20% of the 5.7 million people with Opioid Use Disorder currently receive medication treatment. We're working to change that.

Want to be part of transforming healthcare delivery? Learn more about our equity crowdfunding campaign on StartEngine by clicking the preview below.

The COPA System is currently under development, has NOT been reviewed by the U.S. Food and Drug Administration and is not available for commercial sale.
This Reg CF offering is made available through StartEngine Primary LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Pioneering Biometrics, Secure Medication Dispensing with Remote Monitoring, Empowering Lives

01/16/2025

New study results published in Innovations in Clinical Neuroscience validate the critical need for take-home methadone treatment accessibility.

On average, patients spent 75 minutes traveling to and receiving their dose at an opioid treatment program clinic, with costs averaging $36.58 per trip. 92% of study participants expressed interest in having more take-home doses to better manage work and family life.

Learn how our COPA™ technology could help transform treatment accessibility while ensuring safety and compliance. Read the full press release on our website: https://www.berkshirebiomedical.com/news

COPA™ is under development and has not been approved for commercial sale by the FDA.

12/19/2024

🌟 Excited to announce Berkshire Biomedical's official presence on Facebook!

We're on a mission to revolutionize personalized medication delivery through innovative technology. Our vision is simple yet powerful: Enhancing patient wellness by leveraging technology to improve medical outcomes.

At Berkshire Biomedical, we're developing the COPA™ (Computerized Oral Prescription Administration) system, designed to bring a new level of precision, security, and compliance to medication delivery through advanced biometric technology and real-time monitoring capabilities.

Stay tuned as we share updates on our journey to transform healthcare delivery. Follow us to learn more about how we're working to ensure the right medication reaches the right person, at the right time.

COPA™ is under development, has not been submitted to FDA, and is Not Available for Commercial Sale.